Selective elimination of undifferentiated human pluripotent stem cells using pluripotent state-specific immunogenic antigen Glypican-3

Marina Okada, Yoshitaka Tada, Tomohisa Seki, Shugo Tohyama, Jun Fujita, Toshihiro Suzuki, Manami Shimomura, Kazuya Ofuji, Yoshikazu Kishino, Kazuaki Nakajima, Sho Tanosaki, Shota Someya, Hideaki Kanazawa, Satoru Senju, Tetsuya Nakatsura, Keiichi Fukuda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Immunogenicity of immature pluripotent stem cells is a topic of intense debate. Immunogenic antigens, which are specific in pluripotent states, have not been described previously. In this study, we identified glypican-3 (GPC3), a known carcinoembryonic antigen, as a pluripotent state-specific immunogenic antigen. Additionally, we validated the applicability of human leukocyte antigen (HLA)-class I-restricted GPC3-reactive cytotoxic T lymphocytes (CTLs) in the removal of undifferentiated pluripotent stem cells (PSCs) from human induced pluripotent stem cell (hiPSC)-derivatives. HiPSCs uniquely express GPC3 in pluripotent states and were rejected by GPC3-reactive CTLs, which were sensitized with HLA-class I-restricted GPC3 peptides. Furthermore, GPC3-reactive CTLs selectively removed undifferentiated PSCs from hiPSC-derivatives in vitro and inhibited tumor formation in vivo. Our results demonstrate that GPC3 works as a pluripotent state-specific immunogenic antigen in hiPSCs and is applicable to regenerative medicine as a method of removing undifferentiated PSCs, which are the main cause of tumor formation.

Original languageEnglish
JournalBiochemical and Biophysical Research Communications
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Glypicans
Pluripotent Stem Cells
Stem cells
Antigens
T-cells
Cytotoxic T-Lymphocytes
Induced Pluripotent Stem Cells
HLA Antigens
Tumors
Derivatives
Regenerative Medicine
Carcinoembryonic Antigen
Neoplasms
Peptides

Keywords

  • Cytotoxic T lymphocytes
  • Glypican-3
  • Immunotherapy
  • Induced pluripotent stem cell
  • Regenerative medicine
  • Tumor formation

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Selective elimination of undifferentiated human pluripotent stem cells using pluripotent state-specific immunogenic antigen Glypican-3. / Okada, Marina; Tada, Yoshitaka; Seki, Tomohisa; Tohyama, Shugo; Fujita, Jun; Suzuki, Toshihiro; Shimomura, Manami; Ofuji, Kazuya; Kishino, Yoshikazu; Nakajima, Kazuaki; Tanosaki, Sho; Someya, Shota; Kanazawa, Hideaki; Senju, Satoru; Nakatsura, Tetsuya; Fukuda, Keiichi.

In: Biochemical and Biophysical Research Communications, 01.01.2019.

Research output: Contribution to journalArticle

Okada, Marina ; Tada, Yoshitaka ; Seki, Tomohisa ; Tohyama, Shugo ; Fujita, Jun ; Suzuki, Toshihiro ; Shimomura, Manami ; Ofuji, Kazuya ; Kishino, Yoshikazu ; Nakajima, Kazuaki ; Tanosaki, Sho ; Someya, Shota ; Kanazawa, Hideaki ; Senju, Satoru ; Nakatsura, Tetsuya ; Fukuda, Keiichi. / Selective elimination of undifferentiated human pluripotent stem cells using pluripotent state-specific immunogenic antigen Glypican-3. In: Biochemical and Biophysical Research Communications. 2019.
@article{e5384f3fd0504084a844e06d497fa4c5,
title = "Selective elimination of undifferentiated human pluripotent stem cells using pluripotent state-specific immunogenic antigen Glypican-3",
abstract = "Immunogenicity of immature pluripotent stem cells is a topic of intense debate. Immunogenic antigens, which are specific in pluripotent states, have not been described previously. In this study, we identified glypican-3 (GPC3), a known carcinoembryonic antigen, as a pluripotent state-specific immunogenic antigen. Additionally, we validated the applicability of human leukocyte antigen (HLA)-class I-restricted GPC3-reactive cytotoxic T lymphocytes (CTLs) in the removal of undifferentiated pluripotent stem cells (PSCs) from human induced pluripotent stem cell (hiPSC)-derivatives. HiPSCs uniquely express GPC3 in pluripotent states and were rejected by GPC3-reactive CTLs, which were sensitized with HLA-class I-restricted GPC3 peptides. Furthermore, GPC3-reactive CTLs selectively removed undifferentiated PSCs from hiPSC-derivatives in vitro and inhibited tumor formation in vivo. Our results demonstrate that GPC3 works as a pluripotent state-specific immunogenic antigen in hiPSCs and is applicable to regenerative medicine as a method of removing undifferentiated PSCs, which are the main cause of tumor formation.",
keywords = "Cytotoxic T lymphocytes, Glypican-3, Immunotherapy, Induced pluripotent stem cell, Regenerative medicine, Tumor formation",
author = "Marina Okada and Yoshitaka Tada and Tomohisa Seki and Shugo Tohyama and Jun Fujita and Toshihiro Suzuki and Manami Shimomura and Kazuya Ofuji and Yoshikazu Kishino and Kazuaki Nakajima and Sho Tanosaki and Shota Someya and Hideaki Kanazawa and Satoru Senju and Tetsuya Nakatsura and Keiichi Fukuda",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.bbrc.2019.02.094",
language = "English",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Selective elimination of undifferentiated human pluripotent stem cells using pluripotent state-specific immunogenic antigen Glypican-3

AU - Okada, Marina

AU - Tada, Yoshitaka

AU - Seki, Tomohisa

AU - Tohyama, Shugo

AU - Fujita, Jun

AU - Suzuki, Toshihiro

AU - Shimomura, Manami

AU - Ofuji, Kazuya

AU - Kishino, Yoshikazu

AU - Nakajima, Kazuaki

AU - Tanosaki, Sho

AU - Someya, Shota

AU - Kanazawa, Hideaki

AU - Senju, Satoru

AU - Nakatsura, Tetsuya

AU - Fukuda, Keiichi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Immunogenicity of immature pluripotent stem cells is a topic of intense debate. Immunogenic antigens, which are specific in pluripotent states, have not been described previously. In this study, we identified glypican-3 (GPC3), a known carcinoembryonic antigen, as a pluripotent state-specific immunogenic antigen. Additionally, we validated the applicability of human leukocyte antigen (HLA)-class I-restricted GPC3-reactive cytotoxic T lymphocytes (CTLs) in the removal of undifferentiated pluripotent stem cells (PSCs) from human induced pluripotent stem cell (hiPSC)-derivatives. HiPSCs uniquely express GPC3 in pluripotent states and were rejected by GPC3-reactive CTLs, which were sensitized with HLA-class I-restricted GPC3 peptides. Furthermore, GPC3-reactive CTLs selectively removed undifferentiated PSCs from hiPSC-derivatives in vitro and inhibited tumor formation in vivo. Our results demonstrate that GPC3 works as a pluripotent state-specific immunogenic antigen in hiPSCs and is applicable to regenerative medicine as a method of removing undifferentiated PSCs, which are the main cause of tumor formation.

AB - Immunogenicity of immature pluripotent stem cells is a topic of intense debate. Immunogenic antigens, which are specific in pluripotent states, have not been described previously. In this study, we identified glypican-3 (GPC3), a known carcinoembryonic antigen, as a pluripotent state-specific immunogenic antigen. Additionally, we validated the applicability of human leukocyte antigen (HLA)-class I-restricted GPC3-reactive cytotoxic T lymphocytes (CTLs) in the removal of undifferentiated pluripotent stem cells (PSCs) from human induced pluripotent stem cell (hiPSC)-derivatives. HiPSCs uniquely express GPC3 in pluripotent states and were rejected by GPC3-reactive CTLs, which were sensitized with HLA-class I-restricted GPC3 peptides. Furthermore, GPC3-reactive CTLs selectively removed undifferentiated PSCs from hiPSC-derivatives in vitro and inhibited tumor formation in vivo. Our results demonstrate that GPC3 works as a pluripotent state-specific immunogenic antigen in hiPSCs and is applicable to regenerative medicine as a method of removing undifferentiated PSCs, which are the main cause of tumor formation.

KW - Cytotoxic T lymphocytes

KW - Glypican-3

KW - Immunotherapy

KW - Induced pluripotent stem cell

KW - Regenerative medicine

KW - Tumor formation

UR - http://www.scopus.com/inward/record.url?scp=85062148622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062148622&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2019.02.094

DO - 10.1016/j.bbrc.2019.02.094

M3 - Article

C2 - 30827508

AN - SCOPUS:85062148622

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

ER -